HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy

Volume: 33, Issue: 1, Pages: 118 - 127
Published: Sep 2, 2019
Abstract
A recent phase II clinical trial showed increased progression-free survival in patients with HER2-positive endometrial serous carcinoma receiving trastuzumab in addition to carboplatin-paclitaxel chemotherapy. Similar to endometrial serous carcinomas, carcinosarcomas of the female genital tract have a dismal prognosis and could potentially benefit from new targeted therapeutic approaches. We aimed to systematically evaluate the characteristics...
Paper Details
Title
HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy
Published Date
Sep 2, 2019
Volume
33
Issue
1
Pages
118 - 127
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.